PubMed Central, Table 1: Endocr Dev. 2010; 19: 1–20. Published online 2010 June 15. doi: 10.1159/000316893.

		Transmission	Protein encoded by the altered gene or causal agent	Age at onset lipodystrophy	Adipose distribution	Clinical and Biological parameters
Genetic	Generalized BSCL1 BSCL2 BSCL3	AR AR AR	AGPAT2 Seipin Caveolin 1	{ Birth or early infancy	{ Complete lipoatrophy	{ Acanthosis nigricans, Dyslipidemia, Diabetes
	Partial FPLD2 Metabolic laminopathy	AD Generally AD	Lamin A/C Lamin A/C	Puberty Puberty	Limbs and buttocks lipoatrophy, increased fat in the face and neck Mild or absent lipodystrophy	{Acanthosis nigricans, Dyslipidemia, Diabetes
	Partial FPLD3	AD	PPARγ	Puberty	Lower body lipoatrophy	Hypertension Acanthosis nigricans Dyslipidemia Diabetes
	Partial AKT2-linked	AD	AKT2/PKB		Partial lipodystrophy	Hypertension Acanthosis nigricans Diabetes
Acquired	Generalized Lawrence syndrome		Unknown Sometimes autoimmune disorders	Childhood or adulthood	Complete lipoatrophy	Sometimes panniculitis Acanthosis nigricans Dyslipidemia Diabetes
	Partial Barraquer-Simmons syndrome		Unknown Lamin B2 proposed but not confirmed	Adolescence or early adulthood	Upper body lipoatrophy Lower body fat accumulation	Uncommon metabolic alterations Sometimes low C3 and membranoproliferative glomerulonephritis
	Generalized or partial HIV-related		Some antiretroviral drugs: stavudine, zidovudine, first generation protease inhibitors	Generally adulthood	Peripheral lipoatrophy Central lipoatrophy or fat accumulation	Dyslipidemia Sometimes diabetes
	Partial related to hypercorticism		Endogenous or exogenous excess cortisol	Generally adulthood	Lower body lipoatrophy Upper body fat accumulation	Dyslipidemia Often diabetes